Stifel Transfers Sage Therapeutics (SAGE), Maintains Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
SAGE Therapeutics (SAGE) Reports Q2 Loss of $0.36
August 7, 2018 6:34 AM EDTSAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($0.36), versus ($1.89) reported last year.
Conditional acceptance granted by U.S. Food and Drug Administration (FDA) for the proprietary name ZULRESSO for Sages intravenous formulation of brexanolone
Continuing to execute commercial build and launch readiness for ZULRESSO (brexanolone injection) in postpartum depression ahead of PDUFA target date of December 19, 2018
Accelerating... More
Piper Jaffray Starts Sage Therapeutics (SAGE ) at Overweight
August 6, 2018 5:34 AM EDTPiper Jaffray initiates coverage on Sage Therapeutics (NASDAQ: SAGE ) with a Overweight rating and a price target of $206.00.
Analyst Danielle Brill believes the company is attractive citing robust supportive data generated in 2018, the novel approach to threat of CNS disorders, the pipeline depth, and consistent management... More
